J&J axes pair of CAR-T therapies for lymphoma, citing evolving market

BioPharma DiveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

FierceBiotechCBER chief Prasad steps aside, deputy takes the reins as search for successor continues

FierceBiotechJ&J axes $5B CAR-T dream months after touting best-in-disease efficacy

Endpoints NewsSummit slips on ivonescimab's apparent interim miss in sign of investor frustration

Endpoints NewsAmgen files update to Tavneos label as FDA escalates push to withdraw

FierceBiotechChutes & Ladders—Astellas appoints new top strategist from Sanofi Japan

FierceBiotechLigand tries to disembark from part of Viking pact, alleging contract breach

CellBringing the genetically minimal cell to life on a computer in 4D

IlluminaCanaccord cuts Illumina stock price target on competition concerns - Investing.com

Endpoints NewsSeaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

Thermo FisherIs Thermo Fisher’s New U.S. Bioprocess Design Center Shaping a Deeper Biopharma Strategy for TMO? - simplywall.st